argenx(US:ARGX) Globenewswire·2026-03-20 20:01Core Viewpoint - argenx SE is holding its Annual General Meeting on May 6, 2026, to discuss key agenda items including the adoption of the 2025 annual accounts and changes to the Board of Directors [1][3]. Meeting Details - The Annual General Meeting will take place at 13:00 CET at the Hilton Amsterdam Schiphol [1]. - Shareholders and other meeting rights holders are invited to attend, with details available on the argenx website [2]. Agenda Items - The agenda includes the discussion and adoption of the 2025 annual accounts, an advisory vote on the 2025 remuneration report, discharge of directors for their 2025 duties, and authorization for the Board to issue shares [3]. - Proposed changes to the Board include the retirement of Jim Daly as non-executive director and Chair of the Commercialization Committee, effective May 6, 2026 [3][4]. - The Board is currently exploring succession options for Jim Daly [3]. Board Appointments - Karen Massey is appointed as executive director for a term of 4 years [8]. - Tim Van Hauwermeiren is appointed as non-executive director for a term of 4 years [8]. - Ana Céspedes and Camilla Sylvest are re-appointed as non-executive directors for terms of 4 years [8]. - Pamela Klein is re-appointed as a non-executive director for a term of 2 years [8]. Company Overview - argenx is a global immunology company focused on severe autoimmune diseases, partnering with academic researchers to develop novel antibody-based medicines [6]. - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its potential in various serious autoimmune diseases [6].